Neurol. praxi. 2021;22(3):236-241 | DOI: 10.36290/neu.2021.028
Immunopathogenesis of coronavirus SARS-CoV-2 infection with respect to the multiple sclerosis
- Ústav klinické imunologie a alergologie, LF UK a FN, Hradec Králové
SARS-CoV-2 virus which is pandemic is entering host cells via interaction between viral spike glycoprotein S with membrane bound ACE2 enzyme. All cells expressing ACE2 are infectable by SARS-CoV-2 virus. The natural course of COVID-19 diseases which is caused by SARS-CoV-2 infection is very individual. It is caused especially by individual immune reactivities. Those infected people who are unable to control and eliminate SARS-CoV-2 infection effectively can progress into severe harm inflammatory response affecting especially respiratory tract. However, SARS-CoV-2 virus could be recognized as neurotropic. Cellular structure of CNS are expressing ACE2 viral receptor. There are several putative ways for SARS-CoV-2 to enter CNS. Patients with multiple sclerosis are not at increased risk of SARS-CoV-2 infection. These patients will profit from active immunisation against SARS-CoV-2. This immunisation will induced at least partial protection against SARS-CoV-2 with very limited risk of harm effects of immunisation.
Keywords: SARS-CoV-2, immunity, CNS, multiple sclerosis, treatment, immunisation.
Received: April 28, 2021; Revised: April 28, 2021; Accepted: April 28, 2021; Prepublished online: April 28, 2021; Published: October 1, 2021 Show citation
References
- Ciotti JR, Valtcheva MV, Cross AH. Effects of MS disease-modifying therapies on responses to vaccinations: a review. Multiple Scler Related Disorders 2020; 45: 102439. https://doi.org/10.1016/j.msard.2020.102439.
Go to original source... 
Go to PubMed... - El-Sayed A, Aleya L, Kamel M. Covid-19: a new emerging respiratory disease from the neurological perspective. Environmental Sci Pollution Research 2021; https://doi.org/10.1007/s11356-021-12969-9. Go to original source... Go to PubMed...
- Jakimovski D, Weinstock-Guttman B, Ramanathan M, Dwyer MG, Zivadinov R. Infections, vaccines and autoimmunity: a multiple sclerosis perspective. Vaccines 2020; 8(50). doi: 10.3390/vaccines8010050. Go to original source... Go to PubMed...
- Jalkh G, Nahed RA, Macaron G, Rensel M. Safety of newer disease modifying therapies in multiple sclerosis. Vaccines 2021; 9(12). https://dx.doi.org/10.3390/vaccines9010012. Go to original source... Go to PubMed...
- Jha NK, Ojha S, Jha SK, Dureja H, Singh SK, Shukla SD, Chellappan DK, Gupta G, Bhardwaj S, Kumar N, Jeyaraman M, Jain R, Muthu S, Kar R, Kumar D, Goswami VK, Ruokolainen J, Kesari KK, Singh SK, Dua K. Evidence of coronavirus (CoV) pathogenesis and emerging pathogen SARS-CoV-2 in the nervous system: a review on neurological impairments and manifestations. J Mol Neurosci 2021; https://doi.org/10.1007/s12031-020-01767-6. Go to original source... Go to PubMed...
- Keyhanian K, Umeton RP, Mohit B, Davoudi V, Hajighasemi F, Ghasemi M. SARS-CoV-2 and nervous system: from pathogenesis to clinical manifestation. J Neuroimmunol 2021; 350: 577436. https://doi.org/10.1016/j.jneuroim.2020.577-436. Go to original source...
- Krejsek J. Aktivní imunizace, reálná cesta ke kontrole šíření infekce koronavirem SARS-CoV-2. Remedia 2021; 31(1): 1-5.
- Otruba P, Bardoň J, Kolář M, Petroušová L, Raška M, Salzman R, Dorňák T, Hluštík P, Hok P, Hvizdošová L, Kaiserová M, Král M, Kurčová S, Mareš J, Mateášiková Z, Menšíková K, Nevrlý M, Polidar P, Rous M, Rous Z, Svrčinová T, Šaňák D, Veverka T, Vaštík M, Čecháková E, Kaňovský P. Neurologické komplikace koronavirové infekce SARS-CoV-2 (covid-19). Neurol. praxi 2020; 21(Suppl. G). Go to original source...
- Möhn N, Konen FF, Pul R, Kleinschnitz Ch, Prüss H, Witte T, Stangel M, Skripuletz T. Experience in multiple sclerosis patients with covid-19 and disease-modifying therapies: a review of 873 published cases. J Clin Med 2020; 9: 4067. doi:10.3390/jcm9124067. Go to original source... Go to PubMed...
- Mares J, Hartung HP. Multiple sclerosis and covid-19. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2020; 164(3): 217-225. Go to original source... Go to PubMed...
- Ruetsch C, Brglez V, Crémoni M, Zorzi K, Fernandez C, Boyer-Suavet S, Benzaken S, Demonchy E, Risso, K, Courjon J, Cua E, Ichai C, Dellamonica J, Passeron T, Seitz-Polski B. Functional exhaustion of type I and II interferons production in severe COVID-19 patients. Front Med 2020; 7: 603961. doi: 10.3389/fmed.2020.603961 Go to original source... Go to PubMed...
- Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell 2021; 184(4): 861-880. Go to original source... Go to PubMed...
- Wang MY, Zhao R, Gao LJ, Gao XF, Wang DP, Cao JM. SARS-CoV-2: structure, biology, and structure-based therapeutics development. Front Cell Infect Microbiol 2020; 10: 587269. doi: 10.3389/fcimb.2020.587269. Go to original source... Go to PubMed...
- Zrzavy T, Kollaritsch H, Rommer PS, Boxberger N, Loebermann M, Wimmer I, Winkelmann A, Zettl UK. Vaccination in multiple sclerosis: friend or foe? Frontiers Immunol 2019; 10: 1883. doi: 10.3389/fimmu.2019.01883. Go to original source... Go to PubMed...
- Zrzavy T, Wimmer I, Rommer PS, Berger T. Immunology of covid-19 and disease-modifying therapies: the good, the bad and the unknown. Eur J Neurol 2020; 0: 1-16. doi: 10.1111/ene.14578. Go to original source... Go to PubMed...